WO2007035961A3 - Anti-cancer therapies - Google Patents

Anti-cancer therapies Download PDF

Info

Publication number
WO2007035961A3
WO2007035961A3 PCT/US2006/037431 US2006037431W WO2007035961A3 WO 2007035961 A3 WO2007035961 A3 WO 2007035961A3 US 2006037431 W US2006037431 W US 2006037431W WO 2007035961 A3 WO2007035961 A3 WO 2007035961A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer therapies
cancer
administration
treated
combination
Prior art date
Application number
PCT/US2006/037431
Other languages
French (fr)
Other versions
WO2007035961A2 (en
Inventor
George Tidmarsh
Donald T Jung
Alan Colowick
Original Assignee
Threshold Pharmaceuticals Inc
George Tidmarsh
Donald T Jung
Alan Colowick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc, George Tidmarsh, Donald T Jung, Alan Colowick filed Critical Threshold Pharmaceuticals Inc
Priority to JP2008532494A priority Critical patent/JP2009509974A/en
Publication of WO2007035961A2 publication Critical patent/WO2007035961A2/en
Publication of WO2007035961A3 publication Critical patent/WO2007035961A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cancer can be treated by administration of glufosfamide alone or in combination with another anticancer agent.
PCT/US2006/037431 2005-09-23 2006-09-25 Anti-cancer therapies WO2007035961A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008532494A JP2009509974A (en) 2005-09-23 2006-09-25 Anti-cancer treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71978705P 2005-09-23 2005-09-23
US60/719,787 2005-09-23
US76059906P 2006-01-20 2006-01-20
US60/760,599 2006-01-20

Publications (2)

Publication Number Publication Date
WO2007035961A2 WO2007035961A2 (en) 2007-03-29
WO2007035961A3 true WO2007035961A3 (en) 2007-08-23

Family

ID=37889585

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037431 WO2007035961A2 (en) 2005-09-23 2006-09-25 Anti-cancer therapies

Country Status (2)

Country Link
JP (1) JP2009509974A (en)
WO (1) WO2007035961A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1711188T3 (en) 2004-02-06 2012-09-10 Threshold Pharmaceuticals Inc anti-cancer therapies
US8765690B2 (en) 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
WO2010019396A1 (en) * 2008-08-13 2010-02-18 Threshold Pharmaceuticals, Inc. Administration of glufosfamide for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662936A (en) * 1993-12-23 1997-09-02 Akzo Nobel, N.V. Sugar-coated pharmaceutical dosage unit

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662936A (en) * 1993-12-23 1997-09-02 Akzo Nobel, N.V. Sugar-coated pharmaceutical dosage unit

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRIASOULIS ET AL.: "Phase I trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially Enhanced Selectively for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European Organization for Research and Treatment of Cancer.....", JOURNAL OF CLINICAL ONCOLOGY, vol. 18, no. 20, 15 October 2000 (2000-10-15), pages 3535 - 3544, XP008102340 *

Also Published As

Publication number Publication date
JP2009509974A (en) 2009-03-12
WO2007035961A2 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
WO2005076888A3 (en) Anti-cancer therapies
WO2007002931A3 (en) Phosphoramidate alkylator prodrugs
EP2205257B8 (en) LAG-3Ig (IMP321) dosage regimes for use in the treatment of cancer
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
IL186662A0 (en) Combination cancer therapy with
WO2008082602A3 (en) Compounds and pharmaceutical compositions for the treatment of liver disorders
PL2012872T3 (en) Treating cancer using electromagnetic fields in combination with anti-cancer drugs
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
AU302970S (en) Bracket comprising of two parts
HK1215683A1 (en) Antifolate agent combinations in the treatment of cancer
WO2009143454A3 (en) Combination antitumor therapy
WO2007112403A3 (en) Prevention and treatment of ischemia-reperfusion injury
WO2008150530A3 (en) Cripto binding molecules
WO2007028154A3 (en) Encapsulated arsenic drugs
WO2010087976A3 (en) Anti-cancer protein-platinum conjugates
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
EP1942884A4 (en) Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
WO2009090651A3 (en) Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
WO2009048980A3 (en) Emp2 antibodies and their therapeutic uses
WO2007021852A3 (en) Transplatinum complexes with n2o2 donor sets as cytotoxic and antitumor agents
EP2277884A8 (en) Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof
HK1117427A1 (en) Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
WO2007035961A3 (en) Anti-cancer therapies
WO2008106491A3 (en) Peptides that interact with topoisomerase i and methods thereof
ZA200709542B (en) Combination therapy in the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008532494

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06815434

Country of ref document: EP

Kind code of ref document: A2